Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients

Table 5

The distribution of adverse events of ASL2/ALT2 in the two groups.

	Grade 1	Grade 2	Grade 3
AST2 in control ()	29 (39.7%)	14 (19.2%)	2 (2.7%)
AST2 in study ()	15 (48.4%)	3 (9.6%)	0 (0.0%)
ALT2 in control ()	30 (41.1%)	9 (12.3%)	0 (0.0%)
ALT2 in study ()	8 (25.8%)	2 (6.5%)	0 (0.0%)